Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging ...
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not ...
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, ...
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer ...
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver ...
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results